October 2025

Treatment strategies for non–small cell lung cancer are increasingly driven by biomarker testing, making rapid and reliable biopsy an area that has attracted new interest among lung cancer specialists.

During a live event, Tony Philip, MD, recommended tailored imaging intervals and avoiding surgery and radiation for desmoid tumors.

During a live event, Barbara T. Ma, MD, MS, examined trial data on lifileucel tumor infiltrating lymphocyte therapy in patients with advanced melanoma.

During a live event, Sumanta K. Pal, MD, discussed lenvatinib dosing and tivozanib efficacy for patients with metastatic renal cell carcinoma.

During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid tumor management.

During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences when choosing CLL treatment.

During a live event, Barbara T. Ma, MD, MS, reviewed guidelines on management and best practices for the use of tumor-infiltrating lymphocytes in melanoma.

During a live event, Sumanta K. Pal, MD, discussed second-line renal cell carcinoma therapies, in the context of a patient with post-immunotherapy progression.